Other studies utilizing anti-PD-1 inhibitors, including nivolumab, in various real-world settings including advanced melanoma, non-small cell lung cancer, and head and neck cancer have demonstrated that favorable PS is predictive of greater OS and PFS [21–23]. Here, PDCD1 is linked to melanoma.